Dergiler / İzmir Tepecik Eğitim Hastanesi Dergisi / 2020 / Cilt: 30 - Sayı: 3

Are MicroRNA 190 and MicroRNA95-3P in the Circulation Can Be Used As Predictive Bioindicators in Differentiated Thyroid Cancer in Patients with Atypia of Undetermined Significance Based on Thyroid Fine Needle Aspiration Biopsy Results?

Tiroid İnce İğne Aspirasyon Biyopsisi Önemi Belirsiz Atipi Olan Hastalarda Dolaşımdaki MikroRNA 190 ve MikroRNA95-3P Diferansiye Tiroid Kanserini Öngörebilen Birer Biyobelirteç Midir?

Sayfa
240–245
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: It has been thought that miRNA 95 and miRNA 190 assessment can help to differentiate thyroid cancer from benign thyroid nodules and may be useful in avoiding unnecessary surgery in patients with atypical cells of undetermined significance.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: It is not always possible to make a definitive diagnosis preoperatively based on thyroid fine needle aspiration biopsy results.
📊
Temel Bulgular & Veri:For this purpose, we aimed to investigate if the circulating microRNA 190 and microRNA 95-3P can be used as biomarkers to distinguish preoperatively between postoperatively detected benign and malign cases based on pathological evaluation of thyroid fine needle aspiration biopsy (FNAB) specimens which established the diagnosis of atypia of undetermined significance (AUS) Method: Patients with diagnosis of atypia of undetermined significance based on preoperative fine needle aspiration biopsy results as malignant (n=29) or benign (29) were included in the study.
💡
Sonuç & Katkı:Conclusion: It has been thought that miRNA 95 and miRNA 190 assessment can help to differentiate thyroid cancer from benign thyroid nodules and may be useful in avoiding unnecessary surgery in patients with atypical cells of undetermined significance.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: It is not always possible to make a definitive diagnosis preoperatively based on thyroid fine needle aspiration biopsy results. Decision making is quite complicated in cases with atypia of undetermined significance (AUS). MicroRNAs have been shown to be associated with the development of neoplasia. For this purpose, we aimed to investigate if the circulating microRNA 190 and microRNA 95-3P can be used as biomarkers to distinguish preoperatively between postoperatively detected benign and malign cases based on pathological evaluation of thyroid fine needle aspiration biopsy (FNAB) specimens which established the diagnosis of atypia of undetermined significance (AUS) Method: Patients with diagnosis of atypia of undetermined significance based on preoperative fine needle aspiration biopsy results as malignant (n=29) or benign (29) were included in the study. Venous blood samples were isolated using a specific miRNA kit. Results: According to the postoperative pathology results, statistically significant differences were detected between thyroid cancer, and benign cases as for circulating levels of miRNA 190 and miRNA 95-3p. Conclusion: It has been thought that miRNA 95 and miRNA 190 assessment can help to differentiate thyroid cancer from benign thyroid nodules and may be useful in avoiding unnecessary surgery in patients with atypical cells of undetermined significance.

Abstract

Amaç: TİİAB’leri ile preoperatif olarak her zaman kesin tanı konulamamaktadır. Önemi belirsiz atipi saptanan olgularda karar vermek oldukça karmaşıktır. MikroRNA’ların neoplazi gelişimi ile ilişkili olduğu gösterilmiştir. Bu amaçla çalışmamızda, TİİAB’ı ÖBA saptanıp posto-operatif patoloji sonucu benign ve malign olan olguları preoperatif dönemde birbirinden ayırt etmede bir biyobelirteç olarak dolaşımdaki mikroRNA 190 ve mikroRNA 95-3P düzeylerinin araştırılması amaçlandı. Yöntem: Çalışmaya preopretif ince iğne aspirasyon biyopsisinde önemi belirsiz atipi saptanan hastalar dahil edildi. Operasyon sonrası patoloji sonucu malign ve benign olan 29’ar hasta çalışmaya alındı. Hastalardan alınan venöz kan örnekler miRNA’ta özgü bir kit kullanılarak izole edildi. Bulgular: Ameliyat sonrası patoloji sonuçlarına göre tiroid kanseri saptanan olgularla benign olan olgular arasında dolaşımdaki miRNA 190 ve miRNA 95-3p arasında istatistiksel olarak anlamlı farklılık saptandı. Sonuç: Dolaşımdaki miRNA 95 ve miRNA 190’ın TİİAB sonucu belirsiz olan hastalarda, tiroid kanserini benign tiroid nodüllerinden ayırmada yardımcı olabileceğini ve gereksiz cerrahiden kaçınmada faydalı olabileceği düşünülmektedir.

🔖

Bu Makaleye Atıf Yap

ÜNSAL, M., ÇATI, E. B., ÜNÜBOL, M., TOPAN, E. D., ERDEMİR, Z., GÜNEY, E., ÇETİN, N., ERDOĞDU, İ. H., ŞEKERCİ, U. U. (2020). Are MicroRNA 190 and MicroRNA95-3P in the Circulation Can Be Used As Predictive Bioindicators in Differentiated Thyroid Cancer in Patients with Atypia of Undetermined Significance Based on Thyroid Fine Needle Aspiration Biopsy Results?. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 30 - Sayı: 3, 240–245. https://ajindex.com/articles/268349

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. The diagnosis and management of thyroid nodules: a review. Jama. 2018
  2. 319(9):914-24. [CrossRef] 2. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Modern Pathology. 2001
  3. 14(4):338. [CrossRef] 3. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016. 2016
  4. [CrossRef] 4. Ambros V. The functions of animal microRNAs. Nature. 2004
  5. 431(7006):350. [CrossRef] 5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004
  6. 116(2):281-97. [CrossRef] 6. Wang Y, Gong W, Yuan Q. Effects of miR-27a upregulation on thyroid cancer cells migration, invasion, and angiogenesis. Genetics and molecular research: GMR. 2016
  7. 15(4). [CrossRef] 7. Liang W, Xie Z, Cui W, Guo Y, Xu L, Wu J, et al. Comprehensive gene and microRNA expression profiling reveals a role for miRNAs in the oncogenic roles of SphK1 in papillary thyroid cancer. Journal of Cancer Research and Clinical Oncology. 2017
  8. 143(4):601-11. [CrossRef] 8. Boufraqech M, Klubo-Gwiezdzinska J, Kebebew E. MicroRNAs in the thyroid. Best Practice & Research Clinical Endocrinology & Metabolism. 2016
  9. 30(5):603-19. [CrossRef] 9. Zhao H, Tang H, Huang Q, Qiu B, Liu X, Fan D, et al. MiR-101 targets USP22 to inhibit the tumorigenesis of papillary thyroid carcinoma. American Journal of Cancer Research. 2016
  10. 6(11):2575. 10. Milas M, Shin J, Gupta M, Novosel T, Nasr C, Brainard J, et al. Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples. Annals of Surgery. 2010
  11. 252(4):643-51. 11. Lee JC, Zhao JT, Clifton‐Bligh RJ, Gill A, Gundara JS, Ip JC, et al. MicroRNA‐222 and MicroRNA‐146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 2013
  12. 119(24):4358-65. [CrossRef] 12. Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2012
  13. 97(6):2084-92. [CrossRef] 13. Cantara S, Pilli T, Sebastiani G, Cevenini G, Busonero G, Cardinale S, et al. Circulating miRNA95 and miRN